AXS 06Alternative Names: AXS-06
Latest Information Update: 12 Jan 2016
At a glance
- Originator Axsome Therapeutics
- Class Analgesics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Pain
Most Recent Events
- 19 Nov 2015 Preclinical trials in Pain in USA (unspecified route) before November 2015